SHPHF.US Sihuan Pharmaceutical Holdings Group Ltd
- Market cap
- USD 1.92B
- P/E
- -
- P/B
- 1.19x
- ROE
- 14.6%
- Dividend yield
- 2.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is SHPHF.US undervalued?
Graham numberThe Graham number of Sihuan Pharmaceutical Holdings Group Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sihuan Pharmaceutical Holdings Group Ltd fundamental analysis
No fundamental analysis for Sihuan Pharmaceutical Holdings Group Ltd yet.
Sihuan Pharmaceutical Holdings Group Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sihuan Pharmaceutical Holdings Group Ltd
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculptu…
Full company profileSihuan Pharmaceutical Holdings Group Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sihuan Pharmaceutical Holdings Group Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.19B | 2.75B | 2.92B | 2.88B | 2.46B | 3.04B | 2.18B | 1.86B | 1.90B | 2.55B | 4.64B |
| Gross Profit | 2.19B | 1.99B | 2.38B | 2.29B | 1.91B | 2.43B | 1.49B | 1.30B | 1.24B | 1.76B | 2.73B |
| Operating Income | 1.94B | 1.47B | 1.72B | 1.39B | 787M | 772M | -1.83B | 162M | -138M | 382M | 1.25B |
| EBITDA | 2.21B | 1.68B | 2.01B | -2.08B | 757M | 986M | -1.54B | 334M | 105M | 608M | 1.27B |
| Net Income | 1.71B | 1.45B | 1.62B | -2.75B | 473M | 417M | -1.91B | -54.0M | -217M | 175M | 899M |
| EPS | 0.17 | 0.15 | 0.17 | -0.29 | 0.05 | 0.04 | -0.21 | -0.01 | -0.02 | 0.02 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 12.2B | 13.6B | 15.4B | 12.6B | 13.0B | 14.5B | 12.1B | 11.5B | 10.5B | 11.6B | 11.6B |
| Total Liabilities | 1.22B | 2.26B | 2.67B | 2.63B | 3.10B | 5.35B | 6.50B | 6.40B | 5.58B | 4.73B | 4.67B |
| Shareholders' Equity | 10.9B | 11.1B | 12.5B | 9.61B | 9.19B | 8.28B | 4.74B | 4.43B | 4.37B | 5.85B | 6.15B |
| Cash & Short-term Investments | 4.12B | 3.80B | 4.62B | 5.27B | 4.94B | 5.79B | 4.79B | 4.48B | 3.88B | 4.10B | 3.72B |
| Total Debt | 8.28M | - | 95.0M | 19.0M | 755M | 1.08B | 1.29B | 1.26B | 974M | 1.01B | 969M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.02B | 1.92B | 1.79B | 1.42B | 227M | 665M | 46.5M | 199M | 244M | -23.6M | -359M |
| Capital Expenditure | 241M | 406M | 262M | 501M | 507M | 601M | 402M | 295M | 186M | 195M | 188M |
| Free Cash Flow | 1.78B | 1.51B | 1.53B | 917M | -280M | 64.3M | -356M | -95.9M | 57.5M | -218M | -547M |
| Ratios | |||||||||||
| ROE | 15.7% | 13.1% | 12.9% | -28.7% | 5.2% | 5.0% | -40.4% | -1.2% | -5.0% | 3.0% | 14.6% |
| ROA | 14.0% | 10.7% | 10.5% | -21.9% | 3.6% | 2.9% | -15.8% | -0.5% | -2.1% | 1.5% | 7.7% |
| Net Profit Margin | 53.6% | 52.8% | 55.5% | -95.7% | 19.2% | 13.7% | -87.8% | -2.9% | -11.4% | 6.9% | 19.4% |
| Debt to Equity | 0.00x | - | 0.01x | 0.00x | 0.08x | 0.13x | 0.27x | 0.28x | 0.22x | 0.17x | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sihuan Pharmaceutical Holdings Group Ltd dividends
- Dividend yield
- 2.32%
- Forward dividend
- -
- Payout ratio
- 51.9%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 90.9M | 0.01 | 51.9% |
| 2024 | CNY 177M | 0.02 | - |
| 2023 | CNY 299M | 0.03 | - |
| 2022 | USD 1.32B | 0.14 | - |
| 2021 | USD 123M | 0.01 | 29.5% |
| 2020 | USD 1.42B | 0.15 | 299.9% |
| 2019 | USD 161M | 0.02 | - |
| 2018 | USD 240M | 0.03 | 14.8% |
| 2017 | CNY 1.14B | 0.12 | 79.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 5, 2014.
Who owns Sihuan Pharmaceutical Holdings Group Ltd
- Insiders 56.31%
- Institutions 7.80%
- Public & others 35.89%
- Shares outstanding 9.12B
- Free float 3.66B
Sihuan Pharmaceutical Holdings Group Ltd company profile
- Company name
- Sihuan Pharmaceutical Holdings Group Ltd
- Ticker
- SHPHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,712
- Fiscal year end
- December
- Address
- Office Tower, Convention Plaza, Wan Chai, Hong Kong
- Phone
- 852 3628 3911
- Website
- sihuanpharm.com
About Sihuan Pharmaceutical Holdings Group Ltd
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions. It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
Sihuan Pharmaceutical Holdings Group Ltd management
7- Dr. Fengsheng CheCo-Founder & Executive Chairman · born 1962
- Dr. Weicheng Guo Ph.D.Deputy Chairman & CEO · born 1964
- Dr. Jionglong Zhang Ph.D.Executive Director · born 1962
- Ms. Yanling ChenJoint Company Secretary & Executive Director · born 1978
- Ms. Xiaomi SongChief Financial Officer · born 1967
- Mr. Kin Wai LiJoint Company Secretary · born 1989
- Mr. Xianhui MengDeputy General Manager · born 1964